Language
English
Publication Date
12-1-2022
Journal
Best Practice & Research Clinical Haematology | Journal
DOI
10.1016/j.beha.2022.101414
PMID
36517124
PMCID
PMC10683866
PubMedCentral® Posted Date
12-1-2023
PubMedCentral® Full Text Version
Author MSS
Abstract
Autologous T cells genetically modified with a CD19 chimeric antigen receptor are an effective therapy for children and adults with relapsed or refractory acute lymphoblastic leukemia with initial response rates ranging from 70 to 85%. Unfortunately, about half of these responding patients will subsequently relapse raising the question of whether allogeneic hemopoietic stem cell transplant should be considered as a consolidative therapy. Currently efforts are focused on defining risk factors for relapse to try and develop algorithms predicting which patients may benefit from allogenic transplant.
Keywords
Child, Adult, Humans, Receptors, Chimeric Antigen, Immunotherapy, Adoptive, Antigens, CD19, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Hematopoietic Stem Cell Transplantation, Recurrence, Chimeric antigen receptor, Acute Lymphoblastic Leukemia, Allogeneic Stem Cell Transplant
Published Open-Access
yes
Recommended Citation
Alejandro Marinos and Helen E Heslop, "Should All Car-T Therapy for Acute Lymphoblastic Leukemia Be Consolidated With Allogeneic Stem Cell Transplant?" (2022). Faculty and Staff Publications. 4608.
https://digitalcommons.library.tmc.edu/baylor_docs/4608